

**Table SII. Treatment characteristics of geriatric patients with psoriasis ( $\geq 80$  years old) compared with patients  $< 80$  years old**

	< 80 years old (n = 892) n (%)	$\geq 80$ years old (n = 58) n (%)	p-value
Current treatment*			
Topicals <sup>a</sup>	584 (66.1)	37 (64.9)	0.850
UV therapy	38 (4.3)	8 (14.0)	0.001
Systemic	359 (40.7)	22 (38.6)	0.759
Conventional systemic <sup>b</sup>	230 (26.0)	17 (29.8)	0.530
Methotrexate	109 (12.3)	6 (10.5)	0.685
Ciclosporin	2 (0.2)	2 (3.5)	0.020
Acitretin	7 (1.4)	1 (1.8)	0.395
Fumaric acid	122 (13.8)	8 (14.0)	0.963
Modern systemic <sup>c</sup>	157 (17.8)	6 (10.5)	0.161
Apremilast	6 (0.7)	0 (0.0)	1.000
Etanercept	23 (2.6)	3 (5.3)	0.205
Adalimumab	59 (6.7)	2 (3.5)	0.575
Infliximab	3 (0.3)	0 (0.0)	1.000
Ustekinumab	46 (5.2)	1 (1.8)	0.355
Secukinumab	9 (1.0)	0 (0.0)	1.000
Ixekizumab	3 (0.3)	0 (0.0)	1.000
Brodalumab	4 (0.5)	0 (0.0)	1.000
Guselkumab	2 (0.2)	0 (0.0)	1.000
Certolizumab pegol	2 (0.2)	0 (0.0)	1.000
No prescribed therapies <sup>d</sup>	144 (16.3)	11 (19.3)	0.555
Requiring assistance with treatment or skin care			0.030
Yes	91 (10.9)	11 (20.8)	
No	742 (89.1)	42 (79.2)	

Values might not add up due to missing values.

\*Patients could select more than 1 answer option.

<sup>a</sup>Including keratolytic agents, corticosteroids, vitamin D derivatives, calcineurin inhibiting agents, coal tar, combination therapies, dithranol (anthralin). <sup>b</sup>Including methotrexate, ciclosporin, acitretin and fumaric acid. <sup>c</sup>Including apremilast, etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, certolizumab pegol. <sup>d</sup>Defined as no prescribed therapies and non-prescription therapies, usage of emollients only, homeopathic treatment, over-the-counter products, and dietary or lifestyle adjustments.

UV: ultraviolet.